Related Experiment Videos
Clozapine as a first treatment for schizophrenia
Margaret G Woerner1, Delbert G Robinson, Jose Ma J Alvir
1Department of Psychiatry, Zucker Hillside Hospital of the North Shore-Long Island Jewish Health System, Glen Oaks, NY 11004, USA. mwoerner@lij.edu
The American Journal of Psychiatry
|August 6, 2003
Summary
Clozapine did not show benefits over conventional antipsychotics for first-episode schizophrenia treatment. High early discontinuation rates prevented studying long-term effects of clozapine in schizophrenia patients.
Area of Science:
- Psychiatry
- Neuroscience
- Pharmacology
Background:
- Schizophrenia is a severe mental disorder.
- Early treatment is crucial for long-term outcomes.
- Clozapine is an atypical antipsychotic with unique efficacy but significant side effects.
Purpose of the Study:
- To investigate if clozapine as a first-line antipsychotic treatment improves the course of schizophrenia.
- To compare clozapine's efficacy against conventional antipsychotics in first-episode patients.
Main Methods:
- A cohort of 34 inpatients with first-episode schizophrenia or schizoaffective disorder received clozapine.
- Patients were followed for up to 4 years, with response defined by sustained remission of positive symptoms.
- Survival analysis was used to compare response rates with a previous study using fluphenazine.
Main Results:
- Nineteen out of 34 patients (55.9%) responded to clozapine, with a median response time of 11 weeks.
- The cumulative response rate at 13 weeks was 66.4%, comparable to fluphenazine.
- High discontinuation rates were observed: 42% stopped clozapine before 6 months, and only 32% remained on it throughout the study.
Conclusions:
- Clozapine demonstrated no acute treatment advantage over conventional antipsychotics for first-episode schizophrenia.
- The high rate of early clozapine discontinuation precluded the assessment of its long-term benefits in this patient group.